Status:
ENROLLING_BY_INVITATION
Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia
Lead Sponsor:
Val Lowe
Conditions:
Alzheimer Disease
Eligibility:
All Genders
60-90 years
Phase:
PHASE2
Brief Summary
This study is being done to research the usefulness of PET/CT imaging for measuring brain inflammation and its relation to Alzheimer's Disease. Additionally, researchers as looking to learn more about...
Detailed Description
Alzheimer's disease (AD) dementia is a devastating illness with no cure. Treatments targeting known pathologic hallmarks of AD, such as amyloid-beta (AB), in symptomatic individuals have proved largel...
Eligibility Criteria
Inclusion
- Males or females 60 years of age or older.
- Meet the requirements for one of the four groups (CU A-, CU A+, MCI A+, AD A+).
- Undergoing neurologic evaluation procedures with cognitive testing in the MCSA or - ADRC for a minimum of about 3 years.
- All participants must have had an amyloid PiB PET scan and MRI brain scan within the previous 6 months.
- Capacity to sign consent or have a legally authorized representative to sign the consent.
Exclusion
- Participants unable to lie down without moving for 20 minutes.
- Women who are pregnant or cannot stop breast feeding for 24 hours.
- Actively taking daily anti-inflammatory medications (NSAIDs, corticosteroids, etc.) except for a small control group.
- Generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning (only acute medication use as an exclusion so as to limit medication interaction but preserve possible chronic systemic inflammation interaction).
- Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc., since the quantitative PET data analysis is based on anatomic criteria that are established uniquely for each subject by registration to his/her MRI.
Key Trial Info
Start Date :
March 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04786223
Start Date
March 30 2021
End Date
March 1 2026
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905